Presentations and Publications
Exclusion of CD8 T Cells from Tumor Epithelium is Associated with Worse Immune Checkpoint Blockade (ICB) Therapy Response and Survival in Non-Small Cell Lung Cancer | Poster | SITC 2024
Spatial transcriptomics analysis reveals association between DDR1-collagen interactions and immune exclusion in human cancers | Poster | SITC 2024
Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer | Poster | SITC 2024
PRTH-101, a Discoidin Domain Receptor 1 (DDR1)-Binding Monoclonal Antibody for Treatment of Thymic Cancers - International Thymic Malignancy Interest Group Annual Meeting 2024 | Poster | ITMIG 2024
Immune phenotypes derived from H&E-stained whole slide images correlate with prognosis and response to checkpoint inhibitors in NSCLC | Abstract | Poster | ASCO 2024
Discoidin Domain Receptor 1 (DDR1) expression is associated with degree of immune exclusion across epithelial tumors | Abstract | Poster | AACR 2024
Machine learning-based identification of H&E-derived morphologic features associated with CD8+ T cell immune exclusion | Abstract | Poster | AACR 2024
3D spatial quantification of lymphocyte infiltration and collagen features in the tumor microenvironment using a novel assay: 3D I/O Pro™ | Abstract | Poster | AACR 2024
Quantitative assessment of the tumor microenvironment using the Aurora™ 3D Spatial Biology Platform | Abstract | Poster | sITC 2023
DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma | Abstract | Poster | SITC 2023
The epithelium-stroma interface serves as a barrier to immune cell infiltration across tumor immune phenotypes in epithelial cancers | Abstract | Poster | sITC 2023
Comparison of multiplex immunofluorescence and H&E-based approaches for characterization of the tumor microenvironment | Abstract | Poster | sITC 2023
A phase 1 first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies | Abstract | Poster | ESMO Congress 2023
High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment | Abstract | Poster | ESMO Congress 2023
A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer | Article | May 26, 2023 | Journal for ImmunoTherapy of Cancer
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop | Article | April 28, 2023 | Journal for ImmunoTherapy of Cancer
Towards a consensus definition of immune exclusion in cancer | Article | March 22, 2023 | Frontiers in Immunology
High Prevalence of Immune exclusion in Cancer as Determined by Pathologist Assessment and Image Analysis | Abstract | Poster | AACR 2023
Discoidin Domain Receptor 1 Expression is Associated with Stroma TGF-beta Signaling in Selected Cancers | Abstract | Poster | SITC 2022
Cancer-Associated Fibroblasts Correlate with Immune Phenotypes in Human Tumors | Abstract | Poster | ESMO Congress 2022
Tumour DDR1 Promotes Collagen Fibre Alignment to Instigate Immune Exclusion | Article | November 3, 2021 | Nature